Ribociclib succinateProduct ingredient for Ribociclib

Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly.

Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.